FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder

Japanese Journal of Clinical Oncology

Volumn 34, Issue 12, 2004, Pages 747-750

  Di Lorenzo, Giuseppe ^a,b   Autorino, Riccardo ^a   Giordano, Antonio ^a   Giuliano, Mario ^a   D'Armiento, Massimo ^a   Bianco, Angelo R ^a   De Placido, Sabino ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Advanced disease; Bladder cancer; Chemotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; PLATINUM COMPLEX; TAXOID; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ARTICLE; BLADDER CARCINOMA; CALORIC INTAKE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; HEMATOLOGIC DISEASE; HUMAN; NUTRITIONAL PARAMETERS; NUTRITIONAL SUPPORT; STOMATITIS; TRANSITIONAL CELL CARCINOMA; AGED; AGRANULOCYTOSIS; ANEMIA; BLADDER TUMOR; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; FEMALE; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY;

AGED; AGED, 80 AND OVER; AGRANULOCYTOSIS; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, TRANSITIONAL CELL; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; ENERGY INTAKE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; STOMATITIS; TAXOIDS; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 14544294549     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyh132     Document Type: Article

References (24)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. Cancer J Clin 2002;52:23-47.
2. Whitmore WF. Management of invasive bladder neoplasms. Semin Urol 1983;1:4-10.
3. Fair WR, Fuks ZY, Sher HI. Cancer of the bladder. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer. Principles and Practice of Oncology. Philadelphia: Lippincott 1993.
4. Loehrer PJ, Einhorn LH, Elson PJ. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066-72.
5. Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomised, multinational, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
6. Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of Eastern Cooperative Oncology Group. J Clin Oncol 1994;12:2264-70.
7. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997;15:3394-8.
8. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 1997;15:1853-7.
9. Witte RS, Elson P, Bono B, et al. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 1997;15:589-93.
10. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II randomised trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin and cisplatin in patients with advanced transitional cell carcinoma. J Clin Oncol 1997;15:2449-55.
11. Krege S, Rembrink V, Borgermann CH, Otto T, Rubben H. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase II study. J Urol 2001;165:67-71.
12. Laudani A, Gebbia V, Leonardi V, Savio G, Borsellino N, Cusimano MP, et al. Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma. Anticancer Res 2004;24:1139-42.
13. Correale P, Messinese S, Caraglia M, Marsili S, Piccolomini A, Petrioli R, et al. A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5 fluorouracil (5FU) and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. Br J Cancer 2004;90:1710-4.
14. Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M, et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 2004;15:493-7.
15. Kish JA, Ensley JF, Jacobs J, et al. A randomized trial of cisplatin (CACP) + 5-fluorouracil infusion and CACP + 5 FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 1985;56:2740-4.
16. Amoroso D, Pronzato P, Bertelli G, et al. Cisplatin and 5 fluorouracil in refractory breast cancer patients: a phase II study. Breast Cancer Res Treat 1988;11:269-71.
17. De Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high dose leucovorin and 5-fluorouracil infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214-9.
18. Andre T, Bensmaine M, Louvet C, et al. Multicenter phase II study of bimonthly high dose leucovorin, fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17:3560-8.
19. Maindrault-Goebel F, Louvet C, Andrè T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and FU regimen as second line therapy for metastatic colon cancer. Eur J Cancer 1999;35:1338-42.
20. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 2000;8:2938-47.
21. Culine S, Rebillard X, Iborra F, Mottet N, Faix A, Ayuso D, et al. Gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the urothelium: a pilot study. Anticancer Res 2003;23:1903-6.
22. Huan SD, Aitken SE, Stewart DJ. A phase II study of 5-fluorouracil and high dose folinic acid in cisplatin-refractory metastatic bladder cancer. Ann Oncol 1995;6:836-7.
23. Otto T, Krege S, Otto B, Goepel M, Rubben H., Therapy with mitomycin C, folinic acid and 5-fluorouracil in treatment of metastatic, refractory urinary bladder carcinoma: phase II study. Urologe A 1997;36:243-7.
24. Logothetis CJ, Hossan E, Reconod G, Sella A, Ellrhorst J, Kilbourn R, et al. 5-Fluorouracil and interferon-alpha in chemotherapy refractory bladder carcinoma: an effective regimen. Anticancer Res 1994;24:1265-9.